Search

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE: To probe into the clinical efficacy of magnesium isoglycyrrhizinate combined with bicyclol in treatment of liver injury after transcatheter arterial chemoembolization (TACE) in patients with primary hepatic carcinoma. METHODS: 197 patients with primary hepatic carcinoma undergoing TACE admitted into Zhongshan Hospital Affiliated to Fudan University from Jan. 2016 to Apr. 2018 were retrospectively selected and divided into control group (68 cases), observation group 1 (65 cases) and observation group 2 (64 cases) according to the application of liver-protecting drugs. The control group was treated with reduced glutathione injection, the observation group 1 was given Bicyclol tablets based on control group, the observation group 2 was given magnesium isoglycyrrhizinate injection combined with bicyclol tablets based on control group. All three groups were administrated on the day of TACE, the medication time of magnesium isoglycyrrhizinate injection was ⩾ 3 days, and the course of bicyclol tablets was ⩾ 4 weeks. The biochemical markers before and after TACE were recorded, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and glutamyl transferase (GGT) and total bilirubin (TBIL) levels, differences in improvements of liver function among three groups were compared. RESULTS: At the second day of TACE and before discharge, the ALT, AST and TBIL levels of three groups were significantly higher than those of before treatment, with extremely statistically significant differences (P< 0.01). Before next TACE, the ALT level of observation group 2 was significantly lower than that of before treatment and the control group, with statistically significant differences (P<0.05); the AST, ALP and TBIL levels of control group were significantly higher than those of before treatment, with statistically significant differences (P<0.05); at the second day after operation and before discharge, the TBIL levels of observation group 2 were significantly lower than those of control group, with statistically significant differences (P<0.05). The total effective rate of observation group 2 was 73.4% (47/64), which was significantly higher than that of the control group (47.1%, 32/68), with statistically significant difference (P< 0.05). CONCLUSION: Magnesium glycyrrhizinate combined with Ihcyclol has a better protective effect on liver injury in patients with primary hepatocellular carcinoma who undergoing TACE, which is better than that of reduced glutathione alone. [ABSTRACT FROM AUTHOR]